Kooperativer Bibliotheksverbund

UID:

Format: 1 Online-Ressource (xii, 254 Seiten).

ISBN: 978-981-136-004-6

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-136-003-9

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-136-005-3

Language: English

DOI: 10.1007/978-981-13-6004-6

URL: Volltext  (URL des Erstveröffentlichers)

URL: Volltext  (URL des Erstveröffentlichers)

URL: lizenzpflichtig

UID:

Format: 1 Online-Ressource (X, 168 p. 47 illus., 21 illus. in color).

ISBN: 978-981-10-4711-4

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-10-4710-7

Language: English

DOI: 10.1007/978-981-10-4711-4

URL: Volltext  (URL des Erstveröffentlichers)

URL: Volltext  (URL des Erstveröffentlichers)

UID:

Format: 1 online resource (294 pages)

ISBN: 0-323-90906-X , 9780323909051

Content: Novel Therapeutic Approaches Targeting Oxidative Stress investigates the role of oxidative stress in disease and explores the latest methods and approaches to targeting oxidative stress for treatment and diagnosis. The book begins with an introduction to oxidative stress and its significance. Subsequent sections cover biochemical methods for detecting free radicals and novel therapeutic approaches for targeting oxidative stress in a number of different diseases. This includes age-related illnesses, neuropsychiatric disorders such as schizophrenia and bipolar disorder, and neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. Novel approaches for targeting oxidative stress in cancer and cardiovascular diseases are also explored. The book then moves on to discuss advances in drug delivery systems and detecting oxidative stress biomarkers using biosensors. It concludes with case studies that illustrate the targeting of oxidative stress and future perspectives.

Note: Intro -- Novel Therapeutic Approaches Targeting Oxidative Stress -- Copyright -- Dedication -- Contents -- Contributors -- Preface -- Acknowledgments -- Chapter 1: Novel therapeutic approaches targeting oxidative stress in mood disorders -- 1 Introduction -- 2 The production of ROS in the brain -- 3 The elimination of ROS in the brain -- 4 Oxidative stress in the brain -- 5 Markers of oxidative stress and mood disorders -- 6 Antioxidant treatments in mood disorders -- 6.1 Antioxidant action of conventional treatments for mood disorders -- 6.2 Antioxidants as an add-on therapy in mood disorders -- 6.2.1 N -acetylcysteine (NAC) -- 6.2.2 Medications with some antioxidant action but not as the main mechanism of action -- 6.3 Manipulation of oxidative stress through lifestyle interventions -- 7 Conclusions -- References -- Chapter 2: Ferroptosis: Oxidative stress and pathophysiology -- 1 Introduction -- 2 Immunology -- 3 Conclusion -- Acknowledgment -- Conflict of interest -- References -- Chapter 3: Oxidative stress and its biological significance -- 1 Introduction -- 2 Oxidative stress in 4-hydroxynonenal (HNE) leading to apoptosis -- 3 Antioxidant supplementation increasing tumorigenesis -- 3.1 Generation of mitochondrial ROS and cancer formation -- 4 Regulation of the cell cycle in the oxidative state -- 5 Viral infections and oxidative stress -- 6 Epigenetic factors and carcinogenesis -- 7 Extracellular superoxide angles and apoptosis -- 7.1 HNE and its adducts in the regulation of transcription factors -- 7.2 How oxidative DNA damage is critical to cancer -- 7.3 Transcription factors that promote cancer -- 7.4 Tumor-promoting genetic changes induce endogenous antioxidants -- 7.5 Endogenous antioxidants promote cell migration and metastasis -- 7.6 N -acetylcysteine-More than an antioxidant. , 7.7 The NADPH relationship and the redox potential -- 7.8 The ambiguous relationship between mitochondrial metabolism and ROS -- 7.9 ROS stimulates or inhibits tumorigenesis -- 7.10 Conceptual and experimental limitations of ROS in the field of redox cancer biology -- 7.11 Cell senescence and tumor suppression -- 7.12 The mTOR pathway is involved in the senescent phenotype and cancer -- 8 Extreme oxidative stress with T cells -- 9 Oxidative stress in lung cancer -- 9.1 Adenocarcinoma (AC) -- 9.2 Squamous cell carcinoma (SqCC) -- 9.3 Large cell carcinoma (LCC) -- 10 Inflammation and lung cancer -- 10.1 Risk factors for lung cancer, inflammatory cytokines, and oxidative stress -- 10.2 Immune response T helper 17 (Th17) -- 10.3 Inflammatory cells and lung cancer -- 10.4 Lung cancer and Tregs -- 10.5 Th17 cells and lung cancer -- 10.6 Quantitative relationships between Th17s and Tregs in lung cancer prognosis -- 10.7 DNA methylation and lung cancer -- 10.8 ATP and NSCLC-dependent chromatin remodeling complexes SWI/SNF -- 10.9 KATs/HDACs and oxidative stress pathways -- 10.10 KEAP1-NRF2-ARE signaling path -- 10.11 Epigenetics, NSCLC, and oxidative stress pathways/genes -- 10.11.1 MRF2 -- 10.12 Heme oxygenase 1 -- 10.13 Hypoxia-inducible factor 1 α -- 10.13.1 PGC-1 α -- 10.14 Oxidative stress, acetylation, and its role in NF-kB regulation -- 11 Oxidative stress in breast cancer -- 11.1 Controversy over the effect of antioxidants on breast cancer -- 11.2 miRNA -- 11.3 miRNA modulates oxidative stress master regulators: NRF2 and NF-kB -- 11.4 miRNA modulates pathways altered by oxidative stress -- 11.4.1 Metabolism -- 11.4.2 Hypoxia -- 12 Response to therapy -- 12.1 BCSCs exhibit lower levels of ROS -- 12.2 Oxidative stress induces premature senescence in BCSCs -- References. , Chapter 4: Novel therapeutic approaches targeting oxidative stress in aging -- 1 Introduction -- 2 Hallmarks of aging -- 3 Causes of aging -- 4 Age-associated diseases -- 4.1 Alzheimer's disease -- 4.2 Cardiovascular disease -- 4.3 Diabetes -- 4.4 Cancer -- 5 Novel therapeutic approaches -- 5.1 Role of quercetin -- 5.2 Role of curcumin -- 5.3 Role of resveratrol -- 6 Liposomes -- 6.1 Charge on liposomes -- 6.2 Role of liposomes in various diseases -- 7 Conclusion -- Acknowledgments -- References -- Chapter 5: Novel therapeutic approaches targeting oxidative stress in neurodegenerative diseases -- 1 Introduction -- 2 Dimensions of aging in the investigation of neurodegeneration -- 2.1 Structural changes in Alzheimer's and Parkinson's disease -- 2.2 Amyloid deposition -- 2.3 Oxidative stress -- 2.4 Immunosenescence -- 2.5 Telomere shortening -- 3 Clinical implications -- 3.1 Antioxidants and antiaging agents' development as drugs -- 3.2 Other pharmacological interventions -- 3.3 Nonpharmacological interventions -- 4 Implications for research -- Acknowledgment -- Conflicts of interest/competing interests -- References -- Chapter 6: The role of oxidative stress in kidney diseases -- 1 Introduction -- 2 Kidney architecture at the cellular level -- 3 Nephrotoxicity and renal pathology -- 3.1 Source of nephrotoxicity -- 3.1.1 Therapeutic agents -- 3.1.2 Environmental pollutants/toxins -- 3.1.3 Diagnostic agents -- 3.1.4 Alternative/health products -- 4 Classification of kidney diseases -- 4.1 Acute renal injury (ARI) -- 4.2 Chronic kidney disease (CKD) -- 5 The chemical species of oxidative stress -- 5.1 Cellular mechanism for the formation of reactive oxygen species -- 6 Cellular antioxidant defense system -- 6.1 Superoxide dismutase (SOD) -- 6.2 Glutathione peroxidase (GSHPX) -- 7 Sources of ROS in the kidneys. , 7.1 NADPH oxidase as a source of ROS -- 7.2 Mitochondrial ROS -- 8 Reactive oxygen species and kidney diseases -- 9 Oxidative stress in the renal tubules -- 9.1 Proximal tubule -- 9.2 Medulla -- 9.3 Distal and collecting duct -- 10 Oxidative stress in the glomerulus -- 11 Oxidative stress in the renal vasculature -- 12 Role of ROS in ischemia and reperfusion (I/R)-induced acute kidney injury -- References -- Chapter 7: The role of oxidative stress and antioxidants across the spectrum of acute coronary syndrome -- 1 Introduction -- 2 Oxidative stress -- 3 Endothelial dysfunction and oxidative stress -- 4 Molecular effects of oxidative stress -- 5 Oxidative stress in coronary artery disease -- 6 Coronary microvascular dysfunction -- 7 Oxidative stress and lipids, protein, and DNA damage -- 8 Therapies for oxidative stress-associated cardiovascular diseases -- 8.1 Antioxidant molecules -- 8.1.1 Nutritional supplements -- 8.1.2 Novel experimental antioxidant-based therapies -- 8.1.3 Antioxidant role of clinical drugs -- 8.2 miRNAs -- 8.3 Limitations -- 9 Conclusions -- References -- Chapter 8: Biosensors in the detection of oxidative stress using discovered biomarkers -- 1 Introduction -- 2 Biosensors -- 2.1 Working principle -- 2.2 Types of biosensors -- 2.2.1 Electrochemical biosensors -- 2.2.2 Optical biosensors -- 2.3 Other biosensors -- 2.3.1 Piezoelectric biosensors -- 2.3.2 Calorimetric biosensors -- 2.3.3 Immuno-biosensors -- 2.3.4 Nano biosensors -- 2.3.5 Fluorescent biosensors -- 2.3.6 Whole cell biosensors -- 3 Biomarkers -- 3.1 Genomic biomarkers -- 3.2 Transcriptomic biomarkers -- 3.3 Proteomic biomarkers -- 3.4 Metabolomic biomarkers -- 4 Overview of discovered biomarkers for oxidative stress -- 5 Management of oxidative stress conditions -- 5.1 Habits and lifestyle -- 5.2 Food and beverage intake. , 5.3 Supplements and antioxidants -- 5.4 Yoga, exercise, and meditation -- 5.5 Healthcare situations and its management -- 6 Research trends and future challenges in development of biosensors -- 7 Conclusion -- Acknowledgments -- References -- Chapter 9: Biochemical approaches/methods in the detection of free radicals -- 1 Introduction -- 2 In vitro methods -- 3 Chemiluminescence-derived methods using luciferine derivatives -- 4 Reduction of cytochrome c -- 5 NBT tests -- 6 Aconitase inactivation -- 7 Boronates -- 8 In vivo methods -- 9 Redox potential of the GSH/GSSG couple -- 10 Measurement of F2-isoprostanes as indicators of lipid per-oxidation -- 11 Reporter assays -- 12 Fluorescent protein-based methods -- 13 Analytical methods -- 14 Fluorescence-dependent methods -- 15 Electron spin resonance (ESR) or electron paramagnetic resonance (EPR) spectroscopy -- 16 Spin trapping technique -- 17 Immuno-spin trapping of macromolecules -- 18 Combined IST and mMRI detection -- 19 Pulse radiolysis -- 20 Chromatography-based techniques -- 21 Other biochemical methods -- 22 Summary -- References -- Chapter 10: Novel therapeutic approaches targeting oxidative stress in breast and lung cancer -- 1 Introduction -- 2 Epidemiology and risk factors -- 2.1 Breast cancer epidemiology -- 2.2 Lung cancer epidemiology -- 3 Role of oxidative stress in cancer pathophysiology -- 3.1 Tumor cellular proliferation and oxidative stress -- 3.2 Metastasis and oxidative stress -- 3.3 Oncogenes, tumor suppressor genes, and oxidative stress -- 3.3.1 MicroRNAs regulated by ROS in cancer -- 4 Classification of breast and lung cancer -- 4.1 Breast cancer -- 4.1.1 Noninvasive breast cancer (NIBC) -- 4.1.2 Invasive breast cancer (IBC) -- 4.1.3 Inflammatory breast cancer -- 4.1.4 Paget's disease of the breast -- 4.1.5 Phyllodes tumor -- 4.2 Lung cancer.

Additional Edition: Print version: Maurya, Pawan Kumar Novel Therapeutic Approaches Targeting Oxidative Stress San Diego : Elsevier Science & Technology,c2022

Language: English

UID:

Format: 1 online resource (432 pages)

ISBN: 0-323-85165-7

Series Statement: Woodhead Publishing Series in Biomaterials

Content: "Nanobioanalytical Approaches to Medical Diagnostics reviews a range of nanobiomaterials and bioanalytical nano-devices for medical diagnostics. Nanobiomaterials and nano-devices are used in various bioanalytical and biochemical systems to provide real-time, point-of-care diagnostics. The specialized properties of nanoparticles allow them to be engineered and adapted to produce the required effect within a bioanalytical or biochemical system – offering targeted and detailed diagnostic results in a range of biomedical applications."--

Additional Edition: Print version: Maurya, Pawan Kumar Nanobioanalytical Approaches to Medical Diagnostics San Diego : Elsevier Science & Technology,c2022 ISBN 9780323851473

Language: English

UID:

Format: 1 online resource (180 pages)

ISBN: 0-12-818824-3

Note: Front Cover -- Nanotechnology in Modern Animal Biotechnology: Concepts and Applications -- Nanotechnology in Modern Animal Biotechnology: Concepts and Applications -- Copyright -- List of Contributors -- Contents -- 1 - Biosensors and Their Application for the Detection of Avian Influenza Virus -- INTRODUCTION -- AVIAN INFLUENZA VIRUS: MOLECULAR BIOLOGY -- BASICS OF BIOSENSORS TECHNOLOGY -- BIOSENSORS IN DETECTION OF AVIAN INFLUENZA -- Piezoelectric Biosensors -- Aptamer-based quartz crystal imbalance sensors -- Optical Biosensors -- Fluorescence-based optical biosensors -- Surface plasmon resonance-based optical biosensors -- Other optical biosensors for AIV detection -- Electrochemical Biosensors -- Electrochemical immunosensors -- Electrochemical genosensors -- CONCLUSION AND FUTURE PROSPECTS -- ACKNOWLEDGMENTS -- REFERENCES -- 2 - Nanoparticle-Mediated Oxidative Stress Monitoring -- OXIDATIVE STRESS MECHANISMS AND CELLULAR EFFECTS -- Free Radicals and Reactive Oxygen and Nitrogen Species -- Electron transport chain -- Chemiosmosis -- Oxidative Stress Induced by Exogenous Agents and Its Consequence -- NANOPARTICLE APPLICATIONS IN EXPERIMENTAL BIOMEDICAL RESEARCH -- Manufacture -- Sustainable Energy -- Medicine -- NANOPARTICLE-MEDIATED OXIDATIVE STRESS MONITORING -- REFERENCES -- 3 - Nanoparticles as Modulators of Oxidative Stress -- INTRODUCTION -- NANOPARTICLES: PHYSICOCHEMICAL PROPERTIES AND NANOTOXICITY -- OXIDATIVE STRESS AND CELLULAR DAMAGE -- GENERATION OF ROS IN NANOPARTICLE-CELL INTERACTIONS -- MECHANISM OF NANOPARTICLE-INDUCED OXIDATIVE STRESS -- ANTIOXIDANT EFFECT OF METAL-BASED NANOPARTICLES -- Silver Nanoparticle -- Cerium Oxide (CeO2) -- Platinum Nanoparticles -- Mesoporous Silica Nanoparticles -- Zinc Oxide Nanoparticles -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES. , 4 - Nanomaterials-Based Next Generation Synthetic Enzymes: Current Challenges and Future Opportunities in Biological Applications -- INTRODUCTION -- NANOMATERIALS EXHIBITING PEROXIDASE-LIKE ACTIVITY -- NANOMATERIALS EXHIBITING OXIDASE-LIKE ACTIVITY -- NANOMATERIALS EXHIBITING SOD-LIKE ACTIVITY -- NANOMATERIALS EXHIBITING CATALASE-LIKE ACTIVITY -- NANOMATERIALS EXHIBITING DUAL ENZYME-LIKE/BIFUNCTIONAL ACTIVITY -- NANOMATERIALS WITH MULTIENZYME MIMETIC ACTIVITY -- NUCLEOTIDES AND NUCLEOSIDE AS A COCATALYST -- CONCLUSIONS AND FUTURE PROSPECTS -- ACKNOWLEDGMENTS -- REFERENCES -- 5 - Nanoparticle-Based Drug Delivery for Chronic Obstructive Pulmonary Disorder and Asthma: Progress and Challenges -- INTRODUCTION -- NANOPARTICLES FOR CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA -- LUNG PHYSIOLOGY AND PARTICLE ABSORPTION -- THE BEHAVIOR OF NANOPARTICLE IN VIVO -- Passive Targeting -- Active Targeting -- APPLICATIONS OF NANOPARTICLES IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA -- Disease Diagnosis -- Targeted Drug Delivery -- Liposomes -- Dendrimers -- Inorganic nanoparticles -- Chitosan -- Gelatin -- Other polymeric nanoparticles -- CURRENT NANOPARTICLE-BASED MEDICINE IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE -- Current Nanoparticle-Based Medicine in Asthma -- TOXICITY IN CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND ASTHMA -- CONCLUSION -- REFERENCES -- FURTHER READING -- 6 - Biosensors in Animal Biotechnology -- INTRODUCTION -- BASIC DESIGN AND OPERATING PRINCIPLE -- Bioreceptors -- Enzymes -- Antibodies -- Nucleic acids -- Whole cells -- Nanoparticles -- Immobilization of Bioreceptors -- Physical methods for immobilization -- Physiosorption -- Retention by gel matrix -- Retention by gel membranes -- Incorporation into composite electrode -- Electropolymerization -- Chemical methods for immobilization -- Direct covalent binding. , Covalent cross-linking -- Transducers -- Electrochemical transducers -- Amperometric transducer -- Potentiometric transducers -- Conductometric transducers -- Impedometric transducers -- Electronic transducers (field-effect transistor based) -- Thermal transducers -- Optical biotransducers -- Gravimetric or piezoelectric transducers -- OUTLINE CLASSIFICATION SCHEMES AND QUALITY INDICATORS OF BIOSENSORS -- Indicators of Biosensor Quality -- Range -- Sensitivity -- Specificity -- Error and accuracy -- Factors Affecting the Biosensor Efficiency -- BIOSENSORS IN ANIMAL CELL CULTURE RESEARCH: CURRENT DEVELOPMENTS -- RECENT DEVELOPMENTS IN BIOSENSORS FOR ANIMAL BIOTECHNOLOGY -- Nanobiosensors -- Lab-on-Chip biosensors -- CERIUM OXIDE AS POTENTIAL ELEMENT FOR BIOSENSORS -- REFERENCES -- 7 - Nanoparticle-Mediated Oxidative Stress Monitoring and Role of Nanoparticle for Treatment of Inflammatory Diseases -- NANOPARTICLES AND OXIDATIVE STRESS -- Introduction -- Oxidative Stress and Antioxidants Mechanism -- Endogenous sources -- Exogenous source -- Oxidative Stress Induced by Metallic and Metallic Oxide Nanoparticle -- Molecular level -- Biochemical level -- Cellular level -- Measurement of Oxidative Stress -- Reactive species measuring in vivo -- Trapping of reactive species -- Ex vivo measurement -- Spin traps -- Aromatic traps -- Measurement of blood pressure -- Reactive species fingerprinting -- Reactive species measurement in cells -- Dichlorofluorescein diacetate -- Dihydrorhodamine 123 -- Luminol -- Diphenyl-1-pyrenylphosphine -- Cis-parinaric acid -- Measurement of the output of probes -- Fluorescence microplate reader -- Flow cytometry -- Confocal microscopy -- Other techniques -- High-performance liquid chromatography -- Amplex red and multiphoton microscopy -- Biosensors -- NANOPARTICLE ROLES IN THE TREATMENT OF INFLAMMATORY DISEASES -- Introduction. , Inflammatory Bowel Diseases -- Inflammatory Lung Diseases -- Ophthalmic Inflammatory Diseases -- Rheumatoid Arthritis -- CONCLUSION -- REFERENCES -- 8 - Biomedical Applications of Nanoparticles -- INTRODUCTION -- CLASSIFICATION OF NANOMATERIALS -- Metallic Nanoparticles -- Nonmetallic/Inorganic Nanoparticles -- Biodegradable Nanoparticles -- BIOMEDICAL APPLICATIONS OF NANOMATERIALS -- Diagnosis -- Drug Delivery -- Liposomes -- Polymeric nanoparticles -- Dendrimers -- Carbon-based nanocarriers -- Polymeric micelles -- NANOPARTICLES FOR TISSUE ENGINEERING AND REGENERATIVE MEDICINE -- FACTORS INFLUENCING UTILITY OF NANOPARTICLES IN BIOMEDICINE -- Materials Used for Nanoparticle Synthesis -- Nanoparticle Characteristics -- Route of Administration -- Nanoparticle Toxicity -- CONCLUSION AND FUTURE PROSPECTS -- ACKNOWLEDGMENTS -- REFERENCES -- 9 - Cancer Cytosensing Approaches in Miniaturized Settings Based on Advanced Nanomaterials and Biosensors -- INTRODUCTION -- CANCER BIOMARKERS USED IN CYTOSENSOR -- NANOMATERIALS USED IN CYTOSENSOR -- CYTOSENSORS FOR CANCER DETECTION -- Lung Cancer -- Breast Cancer -- Gastointestinal Cancer -- Prostate Cancer -- Ovarian Cancer -- CONCLUSION -- ACKNOWLEDGMENTS -- REFERENCES -- 10 - Nanotherapeutics: A Novel and Powerful Approach in Modern Healthcare System -- INTRODUCTION -- NANO FORMULATIONS -- Nanogel -- Nanoemulsion -- Nanocapsules -- Nanosponges -- Solid Lipid Nanoparticles -- Dendrimers -- APPLICATIONS OF NANOTHERAPEUTICS SYSTEM -- Nanomaterials for Implantation -- Nanomaterials for Nonviral Gene and Protein Delivery in Cancer Therapy -- Usage of Nanomaterial in the Photodynamic Therapy -- Applications of Nanoparticles in Medical Imaging for Diagnostic Approach -- Role of Nanoparticles in Biosensors -- Nanoparticles for Blood Purification -- SAFETY AND HAZARDS OF NANOTHERAPEUTICS. , CONCLUSION AND FUTURE PROSPECTIVE -- ACKNOWLEDGMENTS -- REFERENCES -- Index -- A -- B -- C -- D -- E -- F -- G -- H -- I -- L -- M -- N -- O -- P -- Q -- R -- S -- T -- U -- W -- Y -- Z -- Back Cover.

Additional Edition: ISBN 0-12-818823-5

Language: English

UID:

Format: 1 online resource (271 pages)

Edition: First edition

ISBN: 0-443-16035-X

Content: Treatment Landscape of Targeted Therapies in Oncology: Challenges and Opportunities provides up-to-date knowledge on antitumor-targeted therapies and immunotherapy. The book's chapters are written by researchers dynamically working/focusing on cancer treatment. The content is designed to help those who are new to the field (beginners) and various specialized scientists and researchers involved in cancer research. For decades, the hallmark of cancer treatment has been conventional chemotherapy. But with the rapid increase in our understanding of the immune system, more and more small molecules, peptides, recombinant antibodies, vaccines and cellular therapeutic modalities are being applied to manipulate the immune response for cancer treatment.

Note: Intro -- Title page -- Table of Contents -- Copyright -- List of contributors -- Preface -- Chapter 1. Biology of cancer: current insights and perspectives -- Abstract -- Introduction -- A perspective on cancer cell -- Epidemiology of cancer -- Clinical features and diagnosis -- Current and emerging treatment strategies -- Modern challenges in cancer therapy -- Emerging/advanced treatment strategies -- Conclusion and future perspectives -- References -- Chapter 2. Evolution of targeted therapies in cancer: opportunities and challenges -- Abstract -- Introduction -- Types of cancer -- Lung cancer -- Breast cancer -- Colorectal cancer -- Brain cancer -- Blood cancer -- Skin cancer -- Cervical cancer -- Targeted therapies in cancer -- Monoclonal antibodies -- Small molecule inhibitors -- Targeted immunotherapy -- Nanomaterials in cancer therapy -- Opportunities and challenges of targeted cancer therapy -- Conclusions -- Acknowledgments -- Conflict of interest -- Glossary words -- Essay type questions -- References -- Chapter 3. Clinical implementation of biomarkers and signaling pathway as novel targeted therapeutics in breast cancer -- Abstract -- Background -- Factors affecting breast cancer -- Classification of breast cancer -- Biomarkers in breast cancer: diagnostic to targeted therapy -- Targeting molecular signaling pathways -- HER2-positive targeted therapies -- HER2-negative targeted therapies -- Targeted therapy as emerging treatment options -- Conclusion and future perspective -- References -- Chapter 4. Targeted therapies in advanced lung cancerâ€"current landscapes and future projects -- Abstract -- Introduction -- What are targeted therapies -- Large molecule inhibitors -- Immunotherapy -- Monoclonal antibodies -- Small molecule inhibitors and their targets -- Conclusion and future perspectives -- Acknowledgment -- References. , Chapter 5. Targeted therapies: emerging biomarkers in advanced melanoma -- Abstract -- Introduction -- Biomarkers in melanoma (prognostic and predictive) -- Malignant melanoma classification, diagnosis and treatment -- Nanotechnology: mechanisms and nanoparticles in melanoma therapies -- Nanosystems for improved targeted therapies in melanoma -- Conclusion -- References -- Chapter 6. Targeting immune checkpoints for cancer therapy -- Abstract -- Introduction -- Immune checkpoints -- Cytotoxic T-lymphocyte-associated antigen-4 signaling pathway: a promising therapeutic target in cancer -- Anti-PD-1/PDL-1 therapy -- Targeting mammalian target of rapamycin pathway for cancer therapy -- Vascular endothelial growth factor pathway in cancer therapy -- Targeting PI3k/Akt pathway -- Targeting mitogen-activated protein kinases network for cancer prevention -- Inhibition of cyclin-dependent kinases for cancer therapy -- Inhibiting epidermal growth factor receptor and human epidermal growth factor receptor 2 for cancer therapy -- Conclusion -- References -- Chapter 7. Glioblastoma targeted therapies: updated approaches from recent biological insights -- Abstract -- Abbreviations -- Introduction -- Various therapies for glioblastoma multiforme -- Conclusion -- References -- Chapter 8. Current trends and future prospects of molecular targeted therapy in head and neck squamous carcinoma -- Abstract -- Abbreviations -- Introduction -- Epidemiology -- Symptoms and pathophysiology -- Diagnosis and prevention -- Therapeutic strategies -- Existing therapies -- Future prospects -- Summary -- References -- Chapter 9. Targeted therapy and drug resistance in gastric and pancreatic cancer -- Abstract -- Targeted therapy and drug resistance in gastric cancer -- Targeted therapy and drug resistance in pancreatic cancer -- References. , Chapter 10. Colorectal cancer heterogeneity and targeted therapy: clinical implications, challenges, and solutions for treatment resistance -- Abstract -- Introduction -- Molecular biology in metastatic colorectal cancer -- Systemic therapy in metastatic colorectal cancer -- Chemotherapy backbone for metastatic colorectal cancer -- Targeted therapy in first-line setting metastatic colorectal cancer -- Anti-VEGF: bevacizumab -- Antiepidermal growth factor receptor: cetuximab, panitumumab -- Immunotherapy -- BRAF-mutated -- KRAS-G12C-mutation in mCRC -- Elderly/frail patients -- Treatment alternatives after first-line -- Anti-VEGF -- Antiepidermal growth factor receptor -- Anti-BRAF+antiepidermal growth factor receptor -- Treatment alternatives in later lines -- Tyrosine kinase inhibitors -- Thymidine-based nucleoside analogs -- Immunotherapy -- Human epidermal growth factor receptor r2-directed therapy -- Rare actionable fusion proteins -- Local ablative therapy -- Conclusion -- References -- Chapter 11. Endometrial cancer: molecular markers and management of advanced-stage disease -- Abstract -- Introduction -- Type 1 versus type 2 -- Classification of endometrial cancer on molecular basis -- Molecular markers of endometrial cancer -- Management of endometrial cancer -- Risk factors for endometrial cancer -- Conclusion -- Acknowledgments -- Statements and declaration -- Glossary items -- Essay-type questions -- References -- Index.

Additional Edition: Print version: Maurya, Pawan Kumar Treatment Landscape of Targeted Therapies in Oncology San Diego : Elsevier Science & Technology,c2023 ISBN 9780443160349

Language: English

UID:

Format: 1 online resource (278 pages) : , color illustrations

ISBN: 0-323-90462-9

Content: Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology: From Basic Research to Advanced Study analyzes the emerging the field of cardio-oncology, reviewing recent advancements in the field, discussing how to monitor and treat cancer survivors for cardiotoxicity, and identifying potential cardiac side effects in novel cancer therapies. By adopting a translational approach, the book first comprehensively covers the basic science, mechanisms and concepts, which is followed by advanced state-of-art of cardio-oncology. Other sections cover tyrosine kinase inhibitors, Anthracyclines, and biomarkers in cardiotoxicity induced by chemotherapeutic drugs, noninvasive cardiovascular imaging techniques, radiotherapy induced cardiovascular, and more. [...] Both traditional chemotherapeutic agents and newer therapies have demonstrated profound cardiovascular toxicities. It is important to understand the mechanisms of these toxicities to establish strategies for the prevention and management of complications—arrhythmias, heart failure, and even death.

Note: Intro -- Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-oncology: From Basic Research to Advanced Study -- Copyright -- Contents -- Contributors -- Preface -- Chapter 1 Overview of changes in the cardiovascular system -- 1 Introduction -- 2 Circulatory system -- 2.1 Pulmonary circulation -- 2.2 Systemic circulation -- 3 Blood vessels -- 3.1 Veins -- 3.2 Arteries -- 3.3 Capillaries -- 4 Heart valves -- 5 Physiology of heart -- 6 Cardiac cycle -- 7 Heart sounds -- 8 Heart rate -- 9 Blood -- 10 Effects on the cardiovascular system due to various physical/environmental factors -- 10.1 Effects due to aging -- 10.2 Effects due to exercise -- 10.3 Effects due to anesthetics -- 11 Conclusion -- References -- Chapter 2 Cardiovascular disease in cancer survivors: Risk and management -- 1 Introduction -- 2 Section 1: Underlying risk factors: Genetic and environmental -- 2.1 Common risk factors -- 2.2 Genetic risk factors -- 2.3 Environmental risk factors -- 2.3.1 Inflammation in CVD and cancer -- 2.3.2 Air pollution -- 2.3.3 Tobacco use and smoking -- 2.3.4 Alcohol consumption -- 2.3.5 Diet -- 2.3.6 Organic and inorganic chemicals -- 3 Section 2: Health behaviors: Overweight and obesity, hyperlipidemia, hypertension, insulin resistance, and metabolic ... -- 3.1 Metabolic syndrome -- 3.2 Overweight and obesity -- 3.3 Insulin resistance -- 3.4 Hyperlipidemia -- 3.5 Hypertension -- 4 Section 3: Management of risk factors -- 5 Conclusion -- References -- Chapter 3 Recent trends in cancer immunotherapy: Pathways and inhibitors -- 1 Introduction -- 2 CTLA-4 and PD-1 pathways -- 2.1 Immune therapy -- 3 PI3K/AKT/mTOR signaling pathways -- 3.1 Immune therapy -- 4 Concluding remarks -- References -- Chapter 4 Stroke risk assessment and atrial fibrillation (AF) in cancer patients -- 1 Introduction. , 2 Association between cancer and atrial fibrillation (AF) -- 3 Management and treatment modalities of AF -- References -- Chapter 5 Biochemistry of biomarkers in cardiotoxicity induced in chemotherapeutic drugs -- 1 Introduction -- 2 Biomarker discovery pipeline -- 3 Prevalence of cancer and its management strategies -- 3.1 Radiation therapy -- 3.2 Chemotherapy -- 4 Cardiotoxicity due to anticancer therapy -- 4.1 Effect of reactive oxygen species (ROS) -- 4.2 Thrombosis -- 4.3 Cardiac mitochondrial dysfunction -- 5 Biomarkers and its molecular aspects in cardiotoxicity -- 5.1 Cardiac troponins (cTn) -- 5.2 Natriuretic peptides (NPs) -- 5.3 Inflammatory biomarkers -- 5.4 Ischemic biomarkers -- 5.5 Biomarkers of endothelial dysfunction -- 6 Future challenges and concluding remarks -- Acknowledgment -- Funding -- Conflict of interest -- Availability of data and materials -- Authors' contribution -- Ethics approval -- Consent for publication -- References -- Chapter 6 Cardiotoxic effects of tyrosine kinase inhibitors directed against VEGFR -- 1 Tumor angiogenesis -- 2 VEGF signaling pathway in angiogenesis -- 3 VEGF pathway inhibitors for cancer treatment -- 4 Cardiotoxic effects of VEGF pathway inhibitors -- 4.1 Bevacizumab -- 4.1.1 Clinical studies -- 4.1.2 Mechanistic studies -- 4.2 Ramucirumab -- 4.3 Sunitinib -- 4.3.1 Clinical studies -- 4.3.2 Mechanistic studies -- 4.4 Sorafenib -- 4.4.1 Clinical studies -- 4.4.2 Mechanistic studies -- 4.5 Pazopanib -- 4.6 Regorafenib -- 4.7 Vandetanib -- 4.8 Cabozantinib -- 4.9 Axitinib -- 5 Cardioprotective agents -- 6 Conclusion -- Acknowledgments -- References -- Chapter 7 Critical insights into cardiotoxicity of anthracyclines -- 1 Introduction -- 2 Mechanism underlying anthracycline-induced cardiotoxicity -- 2.1 DNA intercalation -- 2.2 Topoisomerase II poison. , 2.3 Reactive oxygen species -- 2.4 DNA adduct formation -- 3 Molecular mechanism of DOX-mediated cardiotoxicity -- 4 Physiological functions of the redox system in CV toxicity -- 5 Strategies to limit doxorubicin cardiotoxicity -- 6 Summary -- References -- Chapter 8 Noninvasive cardiovascular imaging techniques -- 1 Introduction -- 1.1 Pretest considerations: Patient history and physical examination -- 2 Echocardiology -- 2.1 Transthoracic echocardiography (TTE) -- 2.2 Transesophageal echocardiography (TEE) -- 2.3 Stress echocardiography -- 2.4 Three-dimensional echocardiography (3D Echo) -- 2.5 Contrast echocardiography -- 3 Magnetic resonance imaging (MRI) -- 4 Cardiac computed tomography -- 5 Radionucleotide imaging -- 6 Myocardial perfusion imaging -- 7 Summary -- References -- Chapter 9 Cardiovascular risk induced by radiotherapy -- 1 Introduction -- 2 Cardiotoxicity -- 3 Risk factors -- 4 Physiopathology -- 5 Heart failure (HF) -- 5.1 Incidence and clinical presentation -- 5.2 Radiation toxicity -- 5.3 Monitoring of cardiotoxicity -- 5.4 Acute and late injuries -- 5.5 Prevention of cardiotoxicity -- 6 Myocardial ischemia -- 7 Systemic arterial hypertension (SAH) -- 7.1 Clinical manifestations/diagnosis -- 7.2 Treatment -- 8 Arrhythmias -- 8.1 Clinical manifestations/diagnosis -- 8.2 Treatment -- 9 Thromboembolism -- 9.1 Diagnosis and risk factors -- 9.2 Prophylaxis -- 10 Cardiotoxicity associated with radiotherapy (RT) -- 10.1 Pericardial diseases and cancer -- 10.1.1 Diagnosis -- 10.1.2 Treatment -- 10.2 Valves -- 10.3 Driving system -- 10.4 Cardiomyopathies -- 10.5 Cardiotoxicity and thymus diseases -- 10.6 Cardiotoxicity for malignant mesotheliomas -- 10.7 Cardiotoxicity after craniospinal irradiation -- 10.8 Cardiotoxicity after total body irradiation. , 11 Recommendations for follow-up after radiotherapy -- 12 Modern radiotherapy techniques -- References -- Chapter 10 Cardiovascular complication from cancer therapy -- 1 Introduction -- 2 Vascular conditions -- 2.1 Atherosclerosis -- 3 Cancer therapy vs atherosclerosis -- 3.1 Cancer therapy vs hypertension -- 3.2 Arterial thrombosis -- 3.3 Pulmonary embolus -- 4 Cardiac structural problem -- 4.1 Valvular heart disease -- 4.2 Pericardial effusion -- 4.3 Cardiac conduction diseases -- 5 Cardiac dysfunction and heart failure -- 5.1 Radiation therapy -- 5.2 Antiangiogenic therapy -- 5.3 Trastuzumab -- References -- Chapter 11 Novel anticancer drugs related to cardiotoxicity -- 1 Introduction -- 2 Clinically used cardioprotective drugs against cardiotoxicity -- 2.1 Dexrazoxane -- 2.2 Antioxidants -- 2.3 Statins -- 2.4 GPCRs -- 3 GPCR-targeted cardioprotective strategies against anticancer-induced cardiotoxicity -- 3.1 β -Blockers -- 3.2 Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers -- 4 Newly identified GPCR agonist against anticancer-mediated cardiotoxicity -- 4.1 Alpha-adrenergic receptor -- 4.2 Adenosine receptor agonists -- 4.3 Ghrelin receptor agonist -- 4.4 Galanin receptor agonists -- 4.5 Melatonin receptor agonists -- 4.6 Apelin receptor agonists -- 4.7 Cannabidiol -- 5 Conclusion -- Conflict of interest -- Ethics approval -- Consent for publication -- References -- Chapter 12 Principles of cardiovascular rehabilitation -- 1 Introduction -- 2 Cardiopulmonary stress testing in prehabilitation, habilitation, and rehabilitation -- 3 Cardiopulmonary exercise testing -- 4 CPET protocol -- 5 Oxygen assimilation -- 6 Respiratory switch ratio -- 7 Ventilator anaerobic ratio -- 8 Positive outcomes of cardiac rehabilitation -- 8.1 Aerobic capacity -- 8.1.1 Expected outcomes. , 8.2 Nutrient -- 8.2.1 Expected outcomes -- 8.3 Smoking -- 8.3.1 Expected outcomes -- 8.4 Alcohol drinking -- 8.5 Behavioral and technical problems management -- 8.5.1 Expected outcomes -- 9 Risk factor for prehabilitation -- 10 Phases of cardiac rehabilitation -- 10.1 Phase 1 -- 10.2 Phase 2 -- 10.3 Phase 3 -- 10.4 Phase 4 -- 11 Is rehabilitation too late? -- 12 A paradigm shift in cardiopulmonary rehabilitation -- References -- Chapter 13 Hematopoietic stem cell transplantation: Sources of cells, cryopreservation, and applications -- 1 Introduction -- 2 History and evolution of HSC and HSCT -- 3 Sources of HSCs -- 3.1 Peripheral blood -- 3.2 Bone marrow -- 3.3 Umbilical cord blood -- 4 Preservation and storage of HSCs -- 5 Applications of HSCT -- 5.1 HSCT in primary immunodeficiency diseases -- 5.1.1 X-linked SCID and JAK3 deficiency -- 5.1.2 IL-7 receptor deficiency -- 5.1.3 Recombination-activating genes deficiency -- 5.2 HSCT in autoimmune diseases -- 5.2.1 Multiple sclerosis -- 5.2.2 Systemic sclerosis and systemic lupus erythematosus -- 5.2.3 Crohn's disease -- 5.3 HSCT in malignancies and cancer -- 6 Complications of HSCT in recipients -- 6.1 Immune-mediated complications -- 6.2 Infections -- 6.3 Secondary malignancies -- 6.4 Medical and procedural risks -- 6.4.1 Developing nontoxic conditioning regimens -- 6.4.2 Immune reconstitution -- 6.4.3 Tissue mismatch -- 6.4.4 Immune evasion -- 7 Summary -- References -- Index.

Additional Edition: Print version: Qamar, Imteyaz Cardiovascular Toxicity and Therapeutic Modalities Targeting Cardio-Oncology San Diego : Elsevier Science & Technology,c2022 ISBN 9780323904612

Language: English

UID:

Format: 1 online resource (294 pages)

ISBN: 0-323-90906-X , 9780323909051

Content: Novel Therapeutic Approaches Targeting Oxidative Stress investigates the role of oxidative stress in disease and explores the latest methods and approaches to targeting oxidative stress for treatment and diagnosis. The book begins with an introduction to oxidative stress and its significance. Subsequent sections cover biochemical methods for detecting free radicals and novel therapeutic approaches for targeting oxidative stress in a number of different diseases. This includes age-related illnesses, neuropsychiatric disorders such as schizophrenia and bipolar disorder, and neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. Novel approaches for targeting oxidative stress in cancer and cardiovascular diseases are also explored. The book then moves on to discuss advances in drug delivery systems and detecting oxidative stress biomarkers using biosensors. It concludes with case studies that illustrate the targeting of oxidative stress and future perspectives.

Note: Intro -- Novel Therapeutic Approaches Targeting Oxidative Stress -- Copyright -- Dedication -- Contents -- Contributors -- Preface -- Acknowledgments -- Chapter 1: Novel therapeutic approaches targeting oxidative stress in mood disorders -- 1 Introduction -- 2 The production of ROS in the brain -- 3 The elimination of ROS in the brain -- 4 Oxidative stress in the brain -- 5 Markers of oxidative stress and mood disorders -- 6 Antioxidant treatments in mood disorders -- 6.1 Antioxidant action of conventional treatments for mood disorders -- 6.2 Antioxidants as an add-on therapy in mood disorders -- 6.2.1 N -acetylcysteine (NAC) -- 6.2.2 Medications with some antioxidant action but not as the main mechanism of action -- 6.3 Manipulation of oxidative stress through lifestyle interventions -- 7 Conclusions -- References -- Chapter 2: Ferroptosis: Oxidative stress and pathophysiology -- 1 Introduction -- 2 Immunology -- 3 Conclusion -- Acknowledgment -- Conflict of interest -- References -- Chapter 3: Oxidative stress and its biological significance -- 1 Introduction -- 2 Oxidative stress in 4-hydroxynonenal (HNE) leading to apoptosis -- 3 Antioxidant supplementation increasing tumorigenesis -- 3.1 Generation of mitochondrial ROS and cancer formation -- 4 Regulation of the cell cycle in the oxidative state -- 5 Viral infections and oxidative stress -- 6 Epigenetic factors and carcinogenesis -- 7 Extracellular superoxide angles and apoptosis -- 7.1 HNE and its adducts in the regulation of transcription factors -- 7.2 How oxidative DNA damage is critical to cancer -- 7.3 Transcription factors that promote cancer -- 7.4 Tumor-promoting genetic changes induce endogenous antioxidants -- 7.5 Endogenous antioxidants promote cell migration and metastasis -- 7.6 N -acetylcysteine-More than an antioxidant. , 7.7 The NADPH relationship and the redox potential -- 7.8 The ambiguous relationship between mitochondrial metabolism and ROS -- 7.9 ROS stimulates or inhibits tumorigenesis -- 7.10 Conceptual and experimental limitations of ROS in the field of redox cancer biology -- 7.11 Cell senescence and tumor suppression -- 7.12 The mTOR pathway is involved in the senescent phenotype and cancer -- 8 Extreme oxidative stress with T cells -- 9 Oxidative stress in lung cancer -- 9.1 Adenocarcinoma (AC) -- 9.2 Squamous cell carcinoma (SqCC) -- 9.3 Large cell carcinoma (LCC) -- 10 Inflammation and lung cancer -- 10.1 Risk factors for lung cancer, inflammatory cytokines, and oxidative stress -- 10.2 Immune response T helper 17 (Th17) -- 10.3 Inflammatory cells and lung cancer -- 10.4 Lung cancer and Tregs -- 10.5 Th17 cells and lung cancer -- 10.6 Quantitative relationships between Th17s and Tregs in lung cancer prognosis -- 10.7 DNA methylation and lung cancer -- 10.8 ATP and NSCLC-dependent chromatin remodeling complexes SWI/SNF -- 10.9 KATs/HDACs and oxidative stress pathways -- 10.10 KEAP1-NRF2-ARE signaling path -- 10.11 Epigenetics, NSCLC, and oxidative stress pathways/genes -- 10.11.1 MRF2 -- 10.12 Heme oxygenase 1 -- 10.13 Hypoxia-inducible factor 1 α -- 10.13.1 PGC-1 α -- 10.14 Oxidative stress, acetylation, and its role in NF-kB regulation -- 11 Oxidative stress in breast cancer -- 11.1 Controversy over the effect of antioxidants on breast cancer -- 11.2 miRNA -- 11.3 miRNA modulates oxidative stress master regulators: NRF2 and NF-kB -- 11.4 miRNA modulates pathways altered by oxidative stress -- 11.4.1 Metabolism -- 11.4.2 Hypoxia -- 12 Response to therapy -- 12.1 BCSCs exhibit lower levels of ROS -- 12.2 Oxidative stress induces premature senescence in BCSCs -- References. , Chapter 4: Novel therapeutic approaches targeting oxidative stress in aging -- 1 Introduction -- 2 Hallmarks of aging -- 3 Causes of aging -- 4 Age-associated diseases -- 4.1 Alzheimer's disease -- 4.2 Cardiovascular disease -- 4.3 Diabetes -- 4.4 Cancer -- 5 Novel therapeutic approaches -- 5.1 Role of quercetin -- 5.2 Role of curcumin -- 5.3 Role of resveratrol -- 6 Liposomes -- 6.1 Charge on liposomes -- 6.2 Role of liposomes in various diseases -- 7 Conclusion -- Acknowledgments -- References -- Chapter 5: Novel therapeutic approaches targeting oxidative stress in neurodegenerative diseases -- 1 Introduction -- 2 Dimensions of aging in the investigation of neurodegeneration -- 2.1 Structural changes in Alzheimer's and Parkinson's disease -- 2.2 Amyloid deposition -- 2.3 Oxidative stress -- 2.4 Immunosenescence -- 2.5 Telomere shortening -- 3 Clinical implications -- 3.1 Antioxidants and antiaging agents' development as drugs -- 3.2 Other pharmacological interventions -- 3.3 Nonpharmacological interventions -- 4 Implications for research -- Acknowledgment -- Conflicts of interest/competing interests -- References -- Chapter 6: The role of oxidative stress in kidney diseases -- 1 Introduction -- 2 Kidney architecture at the cellular level -- 3 Nephrotoxicity and renal pathology -- 3.1 Source of nephrotoxicity -- 3.1.1 Therapeutic agents -- 3.1.2 Environmental pollutants/toxins -- 3.1.3 Diagnostic agents -- 3.1.4 Alternative/health products -- 4 Classification of kidney diseases -- 4.1 Acute renal injury (ARI) -- 4.2 Chronic kidney disease (CKD) -- 5 The chemical species of oxidative stress -- 5.1 Cellular mechanism for the formation of reactive oxygen species -- 6 Cellular antioxidant defense system -- 6.1 Superoxide dismutase (SOD) -- 6.2 Glutathione peroxidase (GSHPX) -- 7 Sources of ROS in the kidneys. , 7.1 NADPH oxidase as a source of ROS -- 7.2 Mitochondrial ROS -- 8 Reactive oxygen species and kidney diseases -- 9 Oxidative stress in the renal tubules -- 9.1 Proximal tubule -- 9.2 Medulla -- 9.3 Distal and collecting duct -- 10 Oxidative stress in the glomerulus -- 11 Oxidative stress in the renal vasculature -- 12 Role of ROS in ischemia and reperfusion (I/R)-induced acute kidney injury -- References -- Chapter 7: The role of oxidative stress and antioxidants across the spectrum of acute coronary syndrome -- 1 Introduction -- 2 Oxidative stress -- 3 Endothelial dysfunction and oxidative stress -- 4 Molecular effects of oxidative stress -- 5 Oxidative stress in coronary artery disease -- 6 Coronary microvascular dysfunction -- 7 Oxidative stress and lipids, protein, and DNA damage -- 8 Therapies for oxidative stress-associated cardiovascular diseases -- 8.1 Antioxidant molecules -- 8.1.1 Nutritional supplements -- 8.1.2 Novel experimental antioxidant-based therapies -- 8.1.3 Antioxidant role of clinical drugs -- 8.2 miRNAs -- 8.3 Limitations -- 9 Conclusions -- References -- Chapter 8: Biosensors in the detection of oxidative stress using discovered biomarkers -- 1 Introduction -- 2 Biosensors -- 2.1 Working principle -- 2.2 Types of biosensors -- 2.2.1 Electrochemical biosensors -- 2.2.2 Optical biosensors -- 2.3 Other biosensors -- 2.3.1 Piezoelectric biosensors -- 2.3.2 Calorimetric biosensors -- 2.3.3 Immuno-biosensors -- 2.3.4 Nano biosensors -- 2.3.5 Fluorescent biosensors -- 2.3.6 Whole cell biosensors -- 3 Biomarkers -- 3.1 Genomic biomarkers -- 3.2 Transcriptomic biomarkers -- 3.3 Proteomic biomarkers -- 3.4 Metabolomic biomarkers -- 4 Overview of discovered biomarkers for oxidative stress -- 5 Management of oxidative stress conditions -- 5.1 Habits and lifestyle -- 5.2 Food and beverage intake. , 5.3 Supplements and antioxidants -- 5.4 Yoga, exercise, and meditation -- 5.5 Healthcare situations and its management -- 6 Research trends and future challenges in development of biosensors -- 7 Conclusion -- Acknowledgments -- References -- Chapter 9: Biochemical approaches/methods in the detection of free radicals -- 1 Introduction -- 2 In vitro methods -- 3 Chemiluminescence-derived methods using luciferine derivatives -- 4 Reduction of cytochrome c -- 5 NBT tests -- 6 Aconitase inactivation -- 7 Boronates -- 8 In vivo methods -- 9 Redox potential of the GSH/GSSG couple -- 10 Measurement of F2-isoprostanes as indicators of lipid per-oxidation -- 11 Reporter assays -- 12 Fluorescent protein-based methods -- 13 Analytical methods -- 14 Fluorescence-dependent methods -- 15 Electron spin resonance (ESR) or electron paramagnetic resonance (EPR) spectroscopy -- 16 Spin trapping technique -- 17 Immuno-spin trapping of macromolecules -- 18 Combined IST and mMRI detection -- 19 Pulse radiolysis -- 20 Chromatography-based techniques -- 21 Other biochemical methods -- 22 Summary -- References -- Chapter 10: Novel therapeutic approaches targeting oxidative stress in breast and lung cancer -- 1 Introduction -- 2 Epidemiology and risk factors -- 2.1 Breast cancer epidemiology -- 2.2 Lung cancer epidemiology -- 3 Role of oxidative stress in cancer pathophysiology -- 3.1 Tumor cellular proliferation and oxidative stress -- 3.2 Metastasis and oxidative stress -- 3.3 Oncogenes, tumor suppressor genes, and oxidative stress -- 3.3.1 MicroRNAs regulated by ROS in cancer -- 4 Classification of breast and lung cancer -- 4.1 Breast cancer -- 4.1.1 Noninvasive breast cancer (NIBC) -- 4.1.2 Invasive breast cancer (IBC) -- 4.1.3 Inflammatory breast cancer -- 4.1.4 Paget's disease of the breast -- 4.1.5 Phyllodes tumor -- 4.2 Lung cancer.

Additional Edition: Print version: Maurya, Pawan Kumar Novel Therapeutic Approaches Targeting Oxidative Stress San Diego : Elsevier Science & Technology,c2022

Language: English

UID:

Format: 1 online resource (294 pages)

ISBN: 0-323-90906-X , 9780323909051

Content: Novel Therapeutic Approaches Targeting Oxidative Stress investigates the role of oxidative stress in disease and explores the latest methods and approaches to targeting oxidative stress for treatment and diagnosis. The book begins with an introduction to oxidative stress and its significance. Subsequent sections cover biochemical methods for detecting free radicals and novel therapeutic approaches for targeting oxidative stress in a number of different diseases. This includes age-related illnesses, neuropsychiatric disorders such as schizophrenia and bipolar disorder, and neurodegenerative diseases like Alzheimer’s and Parkinson’s disease. Novel approaches for targeting oxidative stress in cancer and cardiovascular diseases are also explored. The book then moves on to discuss advances in drug delivery systems and detecting oxidative stress biomarkers using biosensors. It concludes with case studies that illustrate the targeting of oxidative stress and future perspectives.

Note: Intro -- Novel Therapeutic Approaches Targeting Oxidative Stress -- Copyright -- Dedication -- Contents -- Contributors -- Preface -- Acknowledgments -- Chapter 1: Novel therapeutic approaches targeting oxidative stress in mood disorders -- 1 Introduction -- 2 The production of ROS in the brain -- 3 The elimination of ROS in the brain -- 4 Oxidative stress in the brain -- 5 Markers of oxidative stress and mood disorders -- 6 Antioxidant treatments in mood disorders -- 6.1 Antioxidant action of conventional treatments for mood disorders -- 6.2 Antioxidants as an add-on therapy in mood disorders -- 6.2.1 N -acetylcysteine (NAC) -- 6.2.2 Medications with some antioxidant action but not as the main mechanism of action -- 6.3 Manipulation of oxidative stress through lifestyle interventions -- 7 Conclusions -- References -- Chapter 2: Ferroptosis: Oxidative stress and pathophysiology -- 1 Introduction -- 2 Immunology -- 3 Conclusion -- Acknowledgment -- Conflict of interest -- References -- Chapter 3: Oxidative stress and its biological significance -- 1 Introduction -- 2 Oxidative stress in 4-hydroxynonenal (HNE) leading to apoptosis -- 3 Antioxidant supplementation increasing tumorigenesis -- 3.1 Generation of mitochondrial ROS and cancer formation -- 4 Regulation of the cell cycle in the oxidative state -- 5 Viral infections and oxidative stress -- 6 Epigenetic factors and carcinogenesis -- 7 Extracellular superoxide angles and apoptosis -- 7.1 HNE and its adducts in the regulation of transcription factors -- 7.2 How oxidative DNA damage is critical to cancer -- 7.3 Transcription factors that promote cancer -- 7.4 Tumor-promoting genetic changes induce endogenous antioxidants -- 7.5 Endogenous antioxidants promote cell migration and metastasis -- 7.6 N -acetylcysteine-More than an antioxidant. , 7.7 The NADPH relationship and the redox potential -- 7.8 The ambiguous relationship between mitochondrial metabolism and ROS -- 7.9 ROS stimulates or inhibits tumorigenesis -- 7.10 Conceptual and experimental limitations of ROS in the field of redox cancer biology -- 7.11 Cell senescence and tumor suppression -- 7.12 The mTOR pathway is involved in the senescent phenotype and cancer -- 8 Extreme oxidative stress with T cells -- 9 Oxidative stress in lung cancer -- 9.1 Adenocarcinoma (AC) -- 9.2 Squamous cell carcinoma (SqCC) -- 9.3 Large cell carcinoma (LCC) -- 10 Inflammation and lung cancer -- 10.1 Risk factors for lung cancer, inflammatory cytokines, and oxidative stress -- 10.2 Immune response T helper 17 (Th17) -- 10.3 Inflammatory cells and lung cancer -- 10.4 Lung cancer and Tregs -- 10.5 Th17 cells and lung cancer -- 10.6 Quantitative relationships between Th17s and Tregs in lung cancer prognosis -- 10.7 DNA methylation and lung cancer -- 10.8 ATP and NSCLC-dependent chromatin remodeling complexes SWI/SNF -- 10.9 KATs/HDACs and oxidative stress pathways -- 10.10 KEAP1-NRF2-ARE signaling path -- 10.11 Epigenetics, NSCLC, and oxidative stress pathways/genes -- 10.11.1 MRF2 -- 10.12 Heme oxygenase 1 -- 10.13 Hypoxia-inducible factor 1 α -- 10.13.1 PGC-1 α -- 10.14 Oxidative stress, acetylation, and its role in NF-kB regulation -- 11 Oxidative stress in breast cancer -- 11.1 Controversy over the effect of antioxidants on breast cancer -- 11.2 miRNA -- 11.3 miRNA modulates oxidative stress master regulators: NRF2 and NF-kB -- 11.4 miRNA modulates pathways altered by oxidative stress -- 11.4.1 Metabolism -- 11.4.2 Hypoxia -- 12 Response to therapy -- 12.1 BCSCs exhibit lower levels of ROS -- 12.2 Oxidative stress induces premature senescence in BCSCs -- References. , Chapter 4: Novel therapeutic approaches targeting oxidative stress in aging -- 1 Introduction -- 2 Hallmarks of aging -- 3 Causes of aging -- 4 Age-associated diseases -- 4.1 Alzheimer's disease -- 4.2 Cardiovascular disease -- 4.3 Diabetes -- 4.4 Cancer -- 5 Novel therapeutic approaches -- 5.1 Role of quercetin -- 5.2 Role of curcumin -- 5.3 Role of resveratrol -- 6 Liposomes -- 6.1 Charge on liposomes -- 6.2 Role of liposomes in various diseases -- 7 Conclusion -- Acknowledgments -- References -- Chapter 5: Novel therapeutic approaches targeting oxidative stress in neurodegenerative diseases -- 1 Introduction -- 2 Dimensions of aging in the investigation of neurodegeneration -- 2.1 Structural changes in Alzheimer's and Parkinson's disease -- 2.2 Amyloid deposition -- 2.3 Oxidative stress -- 2.4 Immunosenescence -- 2.5 Telomere shortening -- 3 Clinical implications -- 3.1 Antioxidants and antiaging agents' development as drugs -- 3.2 Other pharmacological interventions -- 3.3 Nonpharmacological interventions -- 4 Implications for research -- Acknowledgment -- Conflicts of interest/competing interests -- References -- Chapter 6: The role of oxidative stress in kidney diseases -- 1 Introduction -- 2 Kidney architecture at the cellular level -- 3 Nephrotoxicity and renal pathology -- 3.1 Source of nephrotoxicity -- 3.1.1 Therapeutic agents -- 3.1.2 Environmental pollutants/toxins -- 3.1.3 Diagnostic agents -- 3.1.4 Alternative/health products -- 4 Classification of kidney diseases -- 4.1 Acute renal injury (ARI) -- 4.2 Chronic kidney disease (CKD) -- 5 The chemical species of oxidative stress -- 5.1 Cellular mechanism for the formation of reactive oxygen species -- 6 Cellular antioxidant defense system -- 6.1 Superoxide dismutase (SOD) -- 6.2 Glutathione peroxidase (GSHPX) -- 7 Sources of ROS in the kidneys. , 7.1 NADPH oxidase as a source of ROS -- 7.2 Mitochondrial ROS -- 8 Reactive oxygen species and kidney diseases -- 9 Oxidative stress in the renal tubules -- 9.1 Proximal tubule -- 9.2 Medulla -- 9.3 Distal and collecting duct -- 10 Oxidative stress in the glomerulus -- 11 Oxidative stress in the renal vasculature -- 12 Role of ROS in ischemia and reperfusion (I/R)-induced acute kidney injury -- References -- Chapter 7: The role of oxidative stress and antioxidants across the spectrum of acute coronary syndrome -- 1 Introduction -- 2 Oxidative stress -- 3 Endothelial dysfunction and oxidative stress -- 4 Molecular effects of oxidative stress -- 5 Oxidative stress in coronary artery disease -- 6 Coronary microvascular dysfunction -- 7 Oxidative stress and lipids, protein, and DNA damage -- 8 Therapies for oxidative stress-associated cardiovascular diseases -- 8.1 Antioxidant molecules -- 8.1.1 Nutritional supplements -- 8.1.2 Novel experimental antioxidant-based therapies -- 8.1.3 Antioxidant role of clinical drugs -- 8.2 miRNAs -- 8.3 Limitations -- 9 Conclusions -- References -- Chapter 8: Biosensors in the detection of oxidative stress using discovered biomarkers -- 1 Introduction -- 2 Biosensors -- 2.1 Working principle -- 2.2 Types of biosensors -- 2.2.1 Electrochemical biosensors -- 2.2.2 Optical biosensors -- 2.3 Other biosensors -- 2.3.1 Piezoelectric biosensors -- 2.3.2 Calorimetric biosensors -- 2.3.3 Immuno-biosensors -- 2.3.4 Nano biosensors -- 2.3.5 Fluorescent biosensors -- 2.3.6 Whole cell biosensors -- 3 Biomarkers -- 3.1 Genomic biomarkers -- 3.2 Transcriptomic biomarkers -- 3.3 Proteomic biomarkers -- 3.4 Metabolomic biomarkers -- 4 Overview of discovered biomarkers for oxidative stress -- 5 Management of oxidative stress conditions -- 5.1 Habits and lifestyle -- 5.2 Food and beverage intake. , 5.3 Supplements and antioxidants -- 5.4 Yoga, exercise, and meditation -- 5.5 Healthcare situations and its management -- 6 Research trends and future challenges in development of biosensors -- 7 Conclusion -- Acknowledgments -- References -- Chapter 9: Biochemical approaches/methods in the detection of free radicals -- 1 Introduction -- 2 In vitro methods -- 3 Chemiluminescence-derived methods using luciferine derivatives -- 4 Reduction of cytochrome c -- 5 NBT tests -- 6 Aconitase inactivation -- 7 Boronates -- 8 In vivo methods -- 9 Redox potential of the GSH/GSSG couple -- 10 Measurement of F2-isoprostanes as indicators of lipid per-oxidation -- 11 Reporter assays -- 12 Fluorescent protein-based methods -- 13 Analytical methods -- 14 Fluorescence-dependent methods -- 15 Electron spin resonance (ESR) or electron paramagnetic resonance (EPR) spectroscopy -- 16 Spin trapping technique -- 17 Immuno-spin trapping of macromolecules -- 18 Combined IST and mMRI detection -- 19 Pulse radiolysis -- 20 Chromatography-based techniques -- 21 Other biochemical methods -- 22 Summary -- References -- Chapter 10: Novel therapeutic approaches targeting oxidative stress in breast and lung cancer -- 1 Introduction -- 2 Epidemiology and risk factors -- 2.1 Breast cancer epidemiology -- 2.2 Lung cancer epidemiology -- 3 Role of oxidative stress in cancer pathophysiology -- 3.1 Tumor cellular proliferation and oxidative stress -- 3.2 Metastasis and oxidative stress -- 3.3 Oncogenes, tumor suppressor genes, and oxidative stress -- 3.3.1 MicroRNAs regulated by ROS in cancer -- 4 Classification of breast and lung cancer -- 4.1 Breast cancer -- 4.1.1 Noninvasive breast cancer (NIBC) -- 4.1.2 Invasive breast cancer (IBC) -- 4.1.3 Inflammatory breast cancer -- 4.1.4 Paget's disease of the breast -- 4.1.5 Phyllodes tumor -- 4.2 Lung cancer.

Additional Edition: Print version: Maurya, Pawan Kumar Novel Therapeutic Approaches Targeting Oxidative Stress San Diego : Elsevier Science & Technology,c2022

Language: English

UID:

Format: 1 Online-Ressource (X, 168 p. 47 illus., 21 illus. in color).

ISBN: 978-981-10-4711-4

Additional Edition: Erscheint auch als Druck-Ausgabe ISBN 978-981-10-4710-7

Language: English

DOI: 10.1007/978-981-10-4711-4

URL: Volltext  (URL des Erstveröffentlichers)